Related Experiment Video
Updated: Oct 6, 2025
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
Is Elevation of Alkaline Phosphatase a Predictive Factor of Response to Alectinib in NSCLC?
Walid Shalata1, Alexander Yakobson1, Rachel Steckbeck2
1The Legacy Heritage Oncology Center & Dr. Larry Norton Institute, Soroka Medical Center, Ben Gurion University of the Negev, Beer Sheva 84105, Israel.
Abstract:
In the following report, we describe a case of alkaline phosphatase (ALP) elevation occurring during treatment with alectinib (Alecensa™), which was administered for anaplastic lymphoma kinase (ALK) mutated metastatic non-small cell lung cancer (mNSCLC). A 51 year-old female with widespread metastatic disease exhibited a rapid and significant response within a very short period to alectinib therapy, accompanied by a rapid increase of ALP to more than six times the upper limit of normal (grade 3) ALP, decreasing to within normal limits within 3 weeks after initiation of therapy without any dose modification.
